Rallybio to Present at Upcoming Investor Conferences in June

Rhea-AI Summary

Rallybio Corporation (Nasdaq: RLYB) announced its participation in two major investor conferences. The first is the Jefferies Healthcare Conference in New York on June 8, 2022, at 10:30 a.m. ET. The second is the JMP Securities Life Sciences Conference, also in New York, scheduled for June 15, 2022, at 10:30 a.m. ET. Investors can access a live webcast of both presentations through Rallybio’s website, with replays available for 30 days post-event. Rallybio focuses on therapies for severe and rare diseases, established in January 2018.

NEW HAVEN, Conn.--(BUSINESS WIRE)-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced its participation in the following upcoming investor conferences:

• Jefferies Healthcare Conference in New York, NY on Wednesday, June 8, 2022 at 10:30 a.m. ET.
• JMP Securities Life Sciences Conference in New York, NY on Wednesday, June 15, 2022 at 10:30 a.m. ET.

A live webcast of each presentation will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcasts will be available for 30 days following each presentation.

About Rallybio
Rallybio is a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases. Since its launch in January 2018, Rallybio has built a portfolio of promising product candidates, which are now in development to address rare diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders. The Company’s mission is being advanced by a team of highly experienced biopharma industry leaders with extensive research, development, and rare disease expertise. Rallybio is headquartered in New Haven, Connecticut, with an additional facility at the University of Connecticut’s Technology Incubation Program in Farmington, Connecticut. For more information, please visit www.rallybio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220531005830/en/

Investor Contact

Steven Tuch

Head of Corporate Development

415-218-0697

stuch@rallybio.com

Ami Bavishi

Head of Investor Relations and Communications

609-477-4536

abavishi@rallybio.com

Hannah Deresiewicz

Stern Investor Relations, Inc.

212-362-1200

hannah.deresiewicz@sternir.com

Media Contact

Tara DiMilia

908-369-7168

Tara.dimilia@tmstrat.com

Source: Rallybio Corporation

FAQ

What conferences is Rallybio Corporation participating in during June 2022?

Rallybio Corporation is participating in the Jefferies Healthcare Conference on June 8, 2022, and the JMP Securities Life Sciences Conference on June 15, 2022.

Where can I watch the Rallybio Corporation conference presentations?

The presentations can be accessed via live webcast on Rallybio’s website under the Events and Presentations section.

What is the focus of Rallybio Corporation's therapies?

Rallybio Corporation focuses on developing life-transforming therapies for patients with severe and rare diseases.

When was Rallybio Corporation founded?

Rallybio Corporation was founded in January 2018.

What is the stock symbol for Rallybio Corporation?

The stock symbol for Rallybio Corporation is RLYB.